Diabetes Drug May Slow Parkinson’s Disease
Exenatide was studied in a randomized, double blind, placebo controlled study. The drug is a glucagon like peptide 1(GLP-1) receptor agonist which improved off time and benefits persisted weeks [...]
Exenatide was studied in a randomized, double blind, placebo controlled study. The drug is a glucagon like peptide 1(GLP-1) receptor agonist which improved off time and benefits persisted weeks [...]
Studies have shown with normal aging and Alzheimer’s disease (AD) that serotonin degeneration occurs. The new study suggests that the serotonin system is affected in mild cognitive [...]